WASHINGTON – FDA epidemiologist David Graham has insisted for years that regulators should remove from the U.S. market GlaxoSmithKline plc's Type II diabetes drug Avandia (rosiglitazone), and a new study demonstrating the medicine is tied to an increased risk of stroke, heart failure and death has given him more ammunition to wage that battle. (BioWorld Today) Read More
